

PRESS RELEASE

FOR IMMEDIATE RELEASE: SEPTEMBER 9, 2013

**NEW HOPE FOR PARAPLEGICS AND TETRAPLEGICS –
9 YEARS AFTER CHRISTOPHER REEVE, A NEW DRUG THAT RESTORES SOME
WALKING CAPABILITIES BEING CLINICALLY TESTED IN CANADA**

QUEBEC CITY, CANADA. – Today, Nordic Life Science Pipeline launches a campaign to recruit 50 research subjects for the first clinical trials of **SPINALON™**, an innovative oral tri-therapy aimed to trigger short episodes of rhythmic leg movements in severely spinal cord-injured subjects. Preclinical data strongly suggest that *Spinalon™* is ideally suited to become a *first-in-class* therapy for spinal locomotor network activation, basic stepping movement generation and treadmill training in chronic, motor-complete, paraplegic and tetraplegic individuals classified as ASIA-A or ASIA-B. In 2009, the company signed an in-licensing agreement with **UNIVERSITÉ LAVAL** for the exclusive rights of developing *Spinalon™*. The study that will last one year (Sept 2013-Sept 2014) has received authorizations from **HEALTH CANADA, US ARMY** (co- sponsor with Nordic LSP) and **MCGILL UNIVERSITY HEALTH CENTER**, where tests (1 day of hospitalization per patient) will be conducted (for eligibility and recruitment, contact Dr. Radhakrishna, 514-934-1934 ext.44185; mohan.radhakrishna@mcgill.ca).

About SPINALON™

Discovered at Université Laval in 2004 by Dr. Pierre Guertin (full professor, Faculty of Medicine), this drug constitutes a novel class of treatment acting as a potent activator of the spinal locomotor network. It is made of already known and regulatory approved molecules normally used by patients with Parkinson's disease or anxiety, aimed in this case to prevent or reduce secondary complications and comorbid problems associated with chronic paralysis.

About Spinal Cord Injury

Based on recent estimates, 1.3 million patients are currently living with a traumatic spinal cord injury in North America. It is the second most common neurological problem after Alzheimer's disease.

About Nordic Life Science Pipeline Inc

Co-founded by M. Mario Vaillancourt and Dr Pierre Guertin, it is an emerging specialty pharmaceutical company based in Quebec City that focuses on developing preclinical- and early clinical-stage therapeutics in the field of neurological diseases and trauma, sexual dysfunction, and aging.

About Université Laval

Located in Quebec's historic capital, a World Heritage City, Université Laval is one of the first universities in North America (Laval 1663, Harvard 1636). Based on research funding, it is ranked among the top ten in Canada.

About U.S. Department of Defense Spinal Cord Injury Research Program

The U.S. Department of Defense via Congressionally Directed Medical Research Programs financially support, on a competitive basis, translational research and clinical trials of promising new therapies.

About McGill University Health Center

The McGill University Health Centre (MUHC) is one of the world's foremost academic health centers. Building on the tradition of medical leadership of its founding hospitals, the MUHC provides exceptional multidisciplinary patient-centric care.